StemCell Institute
Launch date
Market cap
€117m
Enterprise valuation
€97m (Public information from Sep 2024)
Share price
JPY1646 7096.T
Tokyo Japan (HQ)
Financials
Estimates*
JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 1.4b | 1.8b | 2.1b | 2.5b | 3.0b | 4.0b | 5.2b |
% growth | (16 %) | 26 % | 17 % | 19 % | 21 % | 33 % | 30 % |
EBITDA | 121m | 309m | 405m | 510m | 710m | 1.3b | 1.8b |
% EBITDA margin | 9 % | 17 % | 19 % | 21 % | 24 % | 32 % | 35 % |
Profit | 62.4m | 134m | 198m | 311m | 500m | 780m | 1.2b |
% profit margin | 4 % | 8 % | 9 % | 13 % | 17 % | 20 % | 22 % |
EV / revenue | - | 9.6x | 10.7x | 7.0x | 5.7x | 4.3x | 3.3x |
EV / EBITDA | - | 55.1x | 55.4x | 34.2x | 24.3x | 13.5x | 9.5x |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Late VC | ||
N/A | N/A | IPO | |
Total Funding | - |